Policy and Legislation
Some standard political campaign ploys are not going to cut it this campaign season say campaign watchers -- at least when coupled with the issue of healthcare.
CMS fears seniors may not be taking advantage of the information available to them because the process is too complex to navigate.
In a 5-4 decision the Supreme Court ruled in favor of healthcare reform marking a momentous occasion for Americans, hospitals, patients and all other parties in the healthcare continuum. However, now that reform has passed what will hospitals be doing differently that they previously hadn’t?
The Food and Drug Administration (FDA) released a proposed rule that most medical devices distributed in the United States carry a unique device identifier (UDI).
Dan Walsh and James Allen, healthcare experts with New York-based PA Consulting Group, provide their views on the implications of the ACA on healthcare reform in general and also, specifically, the implications for payers, state governments and the pharmaceutical industry.
While one survey found a slight uptick in the popularity of Obamacare since the Supreme Court handed down its ruling on the Affordable Care Act, the larger question pertains to whether or not the legislative victory will help President Obama in the long-run, and that jury is still out.
The Department of Health and Human Services (HHS) has awarded more than $971 million to continue improving preparedness and health outcomes for a wide range of public health threats within every state, eight U.S. territories and four of the nation's largest metropolitan areas, HHS officials announced Monday.
A new tracking poll conducted by Kaiser Family Foundation in the wake of the Supreme Court ruling on the Affordable Care Act showed that slightly more Americans approved of the decision with 47 percent voicing approval and 43 percent disapproving.
Large pharmaceutical company GlaxoSmithKline (GSK) has agreed to pay $3 billion in order to resolve charges of engaging in illegal schemes related to unlawful marketing and pricing of some of the drugs it manufactures in what has become the largest healthcare fraud scheme in the country's history.
As part of the ACA, the Supreme Court upheld a new tax provision intended to help fund healthcare reform -- a 2.3 percent excise tax on medical device sales beginning Jan. 1, 2013.